search
Back to results

Covers to Improve Esthetic Outcome After Surgery for Chronic Subdural Hematoma (CORRECT-SCAR)

Primary Purpose

Hematoma, Subdural, Chronic, Hematoma, Subdural, Intracranial, Haematoma;Subdural;Traumatic

Status
Completed
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Placement of burr-hole covers
No placement of burr-hole covers
Sponsored by
University of Zurich
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hematoma, Subdural, Chronic focused on measuring Burr hole cover, Chronic subdural hematoma, Trepanation, Aesthetic outcome, Complications, Patient satisfaction, Burr hole plate, Scar, Skin depression

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Participants fulfilling all of the following inclusion criteria are eligible for the study:

  • Patients with first-time cSDH (hypodense, isodense, hyperdense or mixed-type in CT-imaging), scheduled for uni- or bilateral double burr hole trepanation under general anesthesia
  • Patient age ≥ 18 years
  • Patient non-comatose at time of inclusion (GCS > 8 points)
  • Patient able to communicate (in terms of ability to hear, see, speak and understand)

The presence of any one of the following exclusion criteria will lead to exclusion of the participant:

  • Patient with recurrent cSDH or previous surgery for cSDH
  • Patient with cSDH treated by craniotomy or by single burr hole trepanation
  • Patient with cSDH treated in local anesthesia
  • Patient unlikely to attend the follow-up (due to reasons of residency, dismal prognosis, etc.)
  • Pregnancy
  • Known allergy against or incompatibility with Titanium
  • Known or suspected non-compliance
  • Inability to follow the study procedures, e.g. due to psychological disorders, dementia, etc. of the participant

Sites / Locations

  • University Hospital Zurich & University of Zurich

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Intervention group

Control group

Arm Description

Both burr-holes are covered by burr-hole covers in patients with unilateral cSDH. In patients with bilateral cSDH, both burr-holes of the intervention side are covered by burr-hole covers.

None of the burr-holes are covered by burr-hole covers in patients with unilateral cSDH. In patients with bilateral cSDH, both burr-holes on the control side are left uncovered.

Outcomes

Primary Outcome Measures

Patient satisfaction with the aesthetic result of the scar
For the primary outcome, patient satisfaction with the aesthetic results of the scars is determined using a patient-rated outcome measure (PROM), the Aesthetic Numeric Analogue (ANA) scale ranging from 0 (dissatisfied) - 10 (very satisfied). Here, on each side, the frontal and parietal scars are measured separately, and the mean scar satisfaction score per side is built by adding the two values and dividing the sum by two in each patient.

Secondary Outcome Measures

Patient satisfaction with the aesthetic result of the scar
Patient satisfaction with the aesthetic results of the scars is determined using the ANA scale ranging from 0 (dissatisfied) - 10 (very satisfied)
Impairment in activities of daily living
Impairment in activities of daily living (ADLs), rated as yes vs. no, with the following options: a) hairdressing, b) combing, c) washing, d) other
Skin depression
Rate of skin depression, rated as yes vs. no
EQ-5D Index
Health-related Quality of Life (HrQoL) - as PROM on the EQ-5D - allowing the calculation of the EQ-5D index that ranges from -0.074 (worst hrQoL) - 1.00 (best hrQoL) using European norms
EQ-5D VAS
HrQoL - as PROM on the EQ-5D - allowing the calculation of the EQ-5D VAS (ranging from 0 (worst hrQoL) - 100 mm (best hrQoL))
Neurological outcome
Neurological outcome - as physician-rated outcome measure by the NIHSS (ranging from 0 (no neurological deficit) - 42 (severe neurological deficits)), performed by a physician who was trained in the use of the scale (certified)
Disability
Disability, determined by the mRS (ranging from 0 (no disability) to 6 (dead)

Full Information

First Posted
November 21, 2018
Last Updated
September 29, 2022
Sponsor
University of Zurich
Collaborators
Stryker European Operations BV
search

1. Study Identification

Unique Protocol Identification Number
NCT03755349
Brief Title
Covers to Improve Esthetic Outcome After Surgery for Chronic Subdural Hematoma
Acronym
CORRECT-SCAR
Official Title
COveRs to impRove EsthetiC ouTcome After Surgery for Chronic Subdural hemAtoma by buRr Hole Trepanation (CORRECT-SCAR) - a Single-blinded, Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Completed
Study Start Date
January 29, 2019 (Actual)
Primary Completion Date
September 19, 2021 (Actual)
Study Completion Date
January 31, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Zurich
Collaborators
Stryker European Operations BV

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The clinical-functional result after frontal and parietal burr-hole trepanation for the treatment of chronic subdural hematoma (cSDH) is effective with regards to control of the hematoma and regression of symptoms (headache, decreased vigilance and neurological deficits). However, in patients the treatment may leave visible depressions of the scalp, just above the trepanation sites, that typically develop gradually after weeks - months after the procedure. A considerable proportion of patients find this aesthetically, functionally and psychologically disturbing; the skin depressions may even cause pain or interfere with activities of daily living, such as combing, etc. An effective method would exist to avoid this undesired treatment effect: Before the skin is closed, a permeable titanium burr-hole plate could be attached above the trepanation site in order to prevent the skin from sinking into the bony defect. However, this is rarely done today, likely because there is no evidence that this treatment modification is effective and safe. Moreover, as material is implanted, this causes additional costs. The primary aim of this study is to evaluate whether the application of burr-hole plates on both the frontal and parietal burr-hole in the context of burr-hole trepanation for the treatment of cSDH can improve patient satisfaction with the aesthetic result of the surgery. In addition, the study is intended to demonstrate that this additional measure will not result in poorer hematoma control, poorer clinical/neurological outcomes, or additional complications for the patient. In a prospective, single-blind and controlled approach, we randomize 80 patients with uni- or bilateral cSDH into an intervention group (with burr-hole plates) or into a control group (without burr-hole plates). The primary end result of the study is the patient's reported satisfaction with the aesthetic outcome of the surgical scar. Secondary results are pain, functionality, neurological status, health-related quality of life, residual hematoma volume, and complications (according to Clavien-Dindo scale; especially re-operation rate for recurring cSDH and infections). The study corresponds to a modern approach, since today's patients not only expect favorable treatment results for their disease, but the therapy should also avoid permanent undesired side-effects, if possible.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hematoma, Subdural, Chronic, Hematoma, Subdural, Intracranial, Haematoma;Subdural;Traumatic
Keywords
Burr hole cover, Chronic subdural hematoma, Trepanation, Aesthetic outcome, Complications, Patient satisfaction, Burr hole plate, Scar, Skin depression

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
As the evacuation of a cSDH encompasses trepanation of the skull with 2 burr-holes per side (each one in the frontal and parietal skull region), we will perform the study as follows: In patients with unilateral cSDH, we will cover either both (intervention group) or none of the burr holes with a burr hole cover (control group). In patients with bilateral cSDH, we will cover one side with burr hole covers (intervention side), while on the other side no burr hole covers are applied (control side).
Masking
Participant
Masking Description
Patients will be blinded for allocation to the study group/side, but surgeons will not be. Patients will not be aware of the study group/side, since the operation takes place under general anesthesia. After surgery, it is not possible to see through the skin, whether or not a burr hole cover has been placed. The fact that patients are blinded for the study group allocation will be mentioned in the discharge letter (in order to inform the family physician), and the neurosurgical team of nurses and physicians will also be informed not to "unblind" the patient. Unblinding (and revealing a participant's allocated intervention) towards the patient is permissible only if the trial is suspended, prematurely terminated due to security concerns or completed.
Allocation
Randomized
Enrollment
83 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention group
Arm Type
Experimental
Arm Description
Both burr-holes are covered by burr-hole covers in patients with unilateral cSDH. In patients with bilateral cSDH, both burr-holes of the intervention side are covered by burr-hole covers.
Arm Title
Control group
Arm Type
Active Comparator
Arm Description
None of the burr-holes are covered by burr-hole covers in patients with unilateral cSDH. In patients with bilateral cSDH, both burr-holes on the control side are left uncovered.
Intervention Type
Device
Intervention Name(s)
Placement of burr-hole covers
Other Intervention Name(s)
Stryker® UN3 BURR HOLE COVER, 20mm, W/TAB, Item code 53-34520, Stryker® UNIII AXS SCREWS, SELF-DRILLING, 1.5 x 4MM, Item code 56-15934
Intervention Description
Placement of a burr-hole cover (Stryker® UN3 BURR HOLE COVER, 20mm, W/TAB, Item code 53-34520) fixed with 2 screws (Stryker® UNIII AXS SCREWS, SELF-DRILLING, 1.5 x 4MM, Item code 56-15934) on each of two burr-holes
Intervention Type
Other
Intervention Name(s)
No placement of burr-hole covers
Intervention Description
In the control group, none of the burr-holes is covered, representing our current standard of care. In patients with bilateral cSDH, none of the burr-holes on the control side are covered with burr-hole covers.
Primary Outcome Measure Information:
Title
Patient satisfaction with the aesthetic result of the scar
Description
For the primary outcome, patient satisfaction with the aesthetic results of the scars is determined using a patient-rated outcome measure (PROM), the Aesthetic Numeric Analogue (ANA) scale ranging from 0 (dissatisfied) - 10 (very satisfied). Here, on each side, the frontal and parietal scars are measured separately, and the mean scar satisfaction score per side is built by adding the two values and dividing the sum by two in each patient.
Time Frame
90 days postoperative +/- 10 days
Secondary Outcome Measure Information:
Title
Patient satisfaction with the aesthetic result of the scar
Description
Patient satisfaction with the aesthetic results of the scars is determined using the ANA scale ranging from 0 (dissatisfied) - 10 (very satisfied)
Time Frame
12 months postoperative +/- 30 days
Title
Impairment in activities of daily living
Description
Impairment in activities of daily living (ADLs), rated as yes vs. no, with the following options: a) hairdressing, b) combing, c) washing, d) other
Time Frame
90 days and 12 months postoperative
Title
Skin depression
Description
Rate of skin depression, rated as yes vs. no
Time Frame
90 days and 12 months postoperative
Title
EQ-5D Index
Description
Health-related Quality of Life (HrQoL) - as PROM on the EQ-5D - allowing the calculation of the EQ-5D index that ranges from -0.074 (worst hrQoL) - 1.00 (best hrQoL) using European norms
Time Frame
90 days and 12 months postoperative
Title
EQ-5D VAS
Description
HrQoL - as PROM on the EQ-5D - allowing the calculation of the EQ-5D VAS (ranging from 0 (worst hrQoL) - 100 mm (best hrQoL))
Time Frame
90 days and 12 months postoperative
Title
Neurological outcome
Description
Neurological outcome - as physician-rated outcome measure by the NIHSS (ranging from 0 (no neurological deficit) - 42 (severe neurological deficits)), performed by a physician who was trained in the use of the scale (certified)
Time Frame
90 days postoperative
Title
Disability
Description
Disability, determined by the mRS (ranging from 0 (no disability) to 6 (dead)
Time Frame
90 days postoperative
Other Pre-specified Outcome Measures:
Title
Home time
Description
Home time, as surrogate marker of disability
Time Frame
90 days and 12 months postoperative
Title
Safety Outcome - intraoperative complication
Description
Any complication occurring during the surgery
Time Frame
Day of surgery
Title
Safety Outcome - postoperative complication
Description
Any deviation from the regular postoperative course will be recorded on the Clavien-Dindo grading scale.
Time Frame
90 days and 12 months postoperative
Title
Safety Outcome - hematoma recurrence
Description
Hematoma recurrence per side requiring re-operation
Time Frame
90 days and 12 months postoperative
Title
Safety Outcome - local wound infection
Description
Local wound infection requiring surgical revision per side
Time Frame
90 days and 12 months postoperative
Title
Radiological Outcome - residual hematoma volume
Description
Residual hematoma volume in ccm3 will be measured per side on the CT scan routinely performed for clinical patient care
Time Frame
90 days postoperative
Title
Radiological Outcome - absolute hematoma clearance
Description
Absolute (in ccm3) hematoma clearance per side will be determined by comparing the pre- and postoperative CT scans
Time Frame
90 days postoperative
Title
Radiological Outcome - relative hematoma clearance
Description
Relative (in %) hematoma clearance per side will be determined by comparing the pre- and postoperative CT scans
Time Frame
90 days postoperative

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Participants fulfilling all of the following inclusion criteria are eligible for the study: Patients with first-time cSDH (hypodense, isodense, hyperdense or mixed-type in CT-imaging), scheduled for uni- or bilateral double burr hole trepanation under general anesthesia Patient age ≥ 18 years Patient non-comatose at time of inclusion (GCS > 8 points) Patient able to communicate (in terms of ability to hear, see, speak and understand) The presence of any one of the following exclusion criteria will lead to exclusion of the participant: Patient with recurrent cSDH or previous surgery for cSDH Patient with cSDH treated by craniotomy or by single burr hole trepanation Patient with cSDH treated in local anesthesia Patient unlikely to attend the follow-up (due to reasons of residency, dismal prognosis, etc.) Pregnancy Known allergy against or incompatibility with Titanium Known or suspected non-compliance Inability to follow the study procedures, e.g. due to psychological disorders, dementia, etc. of the participant
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Martin N Stienen, MD, FEBNS
Organizational Affiliation
University of Zurich & University Hospital Zurich
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Luca Regli, MD
Organizational Affiliation
University of Zurich & University Hospital Zurich
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Menno R Germans, MD, PhD
Organizational Affiliation
Universitätsspital Zürich
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Zurich & University of Zurich
City
Zürich
State/Province
ZH
ZIP/Postal Code
8091
Country
Switzerland

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
IPD will be made available on reasonable request, once the results are published and if approved by the institutional review board (KEK-ZH).
IPD Sharing Time Frame
After the results are published.
IPD Sharing Access Criteria
IPD will be made available on reasonable request, once the results are published and if approved by the institutional review board (KEK-ZH).
Citations:
PubMed Identifier
30155645
Citation
Vasella F, Akeret K, Smoll NR, Germans MR, Jehli E, Bozinov O, Regli L, Stienen MN; CORRECT SCAR study group. Improving the aesthetic outcome with burr hole cover placement in chronic subdural hematoma evacuation-a retrospective pilot study. Acta Neurochir (Wien). 2018 Nov;160(11):2129-2135. doi: 10.1007/s00701-018-3659-9. Epub 2018 Aug 28.
Results Reference
background
PubMed Identifier
31675709
Citation
Velz J, Vasella F, Akeret K, Dias SF, Jehli E, Bozinov O, Regli L, Germans MR, Stienen MN; CORRECT-SCAR study group. Patterns of care: burr-hole cover application for chronic subdural hematoma trepanation. Neurosurg Focus. 2019 Nov 1;47(5):E14. doi: 10.3171/2019.8.FOCUS19245.
Results Reference
background
PubMed Identifier
31811007
Citation
Stienen MN, Akeret K, Vasella F, Velz J, Jehli E, Scheffler P, Voglis S, Bichsel O, Smoll NR, Bozinov O, Regli L, Germans MR; CORRECT-SCAR study group*. COveRs to impRove AesthetiC ouTcome after Surgery for Chronic subdural haemAtoma by buRr hole trepanation (CORRECT-SCAR): protocol of a Swiss single-blinded, randomised controlled trial. BMJ Open. 2019 Dec 6;9(12):e031375. doi: 10.1136/bmjopen-2019-031375.
Results Reference
background

Learn more about this trial

Covers to Improve Esthetic Outcome After Surgery for Chronic Subdural Hematoma

We'll reach out to this number within 24 hrs